お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
907910

感染症診断の世界市場

Infectious Disease Diagnostics

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 476 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.25円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

感染症診断の世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 476 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の感染症診断市場を調査し、市場の概要、セグメント(技術・製品・サービス)・地域別の市場シェア、需要動向、売上額の推移と予測、市場の成長要因、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
    • 免疫診断(技術)
    • ポリメラーゼ連鎖反応(PRC)(技術)
    • 次世代シーケンサー(NGS)(技術)
    • アッセイ・キット・試薬(製品・サービス)
    • サービス・ソフトウェア(製品・サービス)
  • 注目企業
  • 市場動向と成長要因
  • 世界市場の見通し

第3章 市場分析

  • 地域市場の分析
  • 米国
    • 市場概要
    • 市場シェア:企業別
    • 免疫診断(技術)
    • ポリメラーゼ連鎖反応(PRC)(技術)
    • 次世代シーケンサー(NGS)(技術)
    • アッセイ・キット・試薬(製品・サービス)
    • サービス・ソフトウェア(製品・サービス)
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他の欧州諸国
  • アジア太平洋地域
  • オーストラリア
  • インド
  • 韓国
  • その他のアジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他のラテンアメリカ諸国
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他の中東諸国
  • アフリカ

第4章 競合情勢

  • ABBOTT LABORATORIES
  • BIO-RAD LABORATORIES
  • DANAHER CORPORATION
  • DIASORIN SPA
  • LUMINEX CORPORATION
  • MERIDIAN BIOSCIENCE
  • QUIDEL CORPORATION
  • ROCHE DIAGNOSTICS AG
  • SIEMENS AG
  • THERMO FISHER SCIENTIFIC
  • BIOMeRIEUX SA

第5章 調査資料

目次
Product Code: MCP12706

Abstract:

Global Infectious Disease Diagnostics Market to Reach $20.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Infectious Disease Diagnostics estimated at US$15.8 Billion in the year 2020, is projected to reach a revised size of US$20.8 Billion by 2027, growing at a CAGR of 4% over the analysis period 2020-2027. Assays, Kits, & Reagents, one of the segments analyzed in the report, is projected to record a 4.7% CAGR and reach US$10.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Instruments segment is readjusted to a revised 3.2% CAGR for the next 7-year period.

The U.S. Market is Estimated at $4.3 Billion, While China is Forecast to Grow at 7.3% CAGR

The Infectious Disease Diagnostics market in the U.S. is estimated at US$4.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2027 trailing a CAGR of 7.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.2% and 3.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Services and Software Segment to Record 3.7% CAGR

In the global Services and Software segment, USA, Canada, Japan, China and Europe will drive the 3.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$3 Billion in the year 2020 will reach a projected size of US$3.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.9 Billion by the year 2027, while Latin America will expand at a 4.6% CAGR through the analysis period.

Select Competitors (Total 41 Featured) -

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • DiaSorin SpA
  • Luminex Corporation
  • Meridian Bioscience, Inc.
  • Quidel Corporation
  • Roche Diagnostics (Schweiz) AG
  • Siemens AG
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Infectious Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Infectious Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Assays, Kits, & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Assays, Kits, & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Assays, Kits, & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Services and Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Services and Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Services and Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Hepatitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Hepatitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Hepatitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for HIV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for HIV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for HIV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for HAI by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for HAI by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for HAI by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for HPV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for HPV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for HPV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for TB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for TB by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Influenza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Influenza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Influenza by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Immunodiagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Immunodiagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Immunodiagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 34: World Current & Future Analysis for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 35: World Historic Review for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: World 15-Year Perspective for PCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 37: World Current & Future Analysis for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 38: World Historic Review for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: World 15-Year Perspective for NGS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 40: World Current & Future Analysis for Hospital by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 41: World Historic Review for Hospital by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: World 15-Year Perspective for Hospital by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 43: World Current & Future Analysis for Research Institute by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 44: World Historic Review for Research Institute by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: World 15-Year Perspective for Research Institute by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 46: USA Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: USA Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: USA 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 49: USA Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: USA Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: USA 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 52: USA Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: USA Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: USA 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 55: USA Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: USA Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: USA 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 58: Canada Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Canada Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Canada 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 61: Canada Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Canada Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Canada 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 64: Canada Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Canada Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Canada 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 67: Canada Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Canada Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Canada 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 70: Japan Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Japan Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Japan 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 73: Japan Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Japan Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Japan 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 76: Japan Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Japan Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Japan 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 79: Japan Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Japan Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Japan 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 82: China Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: China Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: China 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 85: China Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: China Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: China 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 88: China Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: China Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: China 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 91: China Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: China Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: China 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 94: Europe Current & Future Analysis for Infectious Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 95: Europe Historic Review for Infectious Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Europe 15-Year Perspective for Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 97: Europe Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Europe Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Europe 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 100: Europe Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Europe Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Europe 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 103: Europe Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Europe Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Europe 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 106: Europe Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Europe Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Europe 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 109: France Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: France Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: France 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 112: France Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: France Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: France 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 115: France Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: France Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: France 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 118: France Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: France Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: France 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 121: Germany Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Germany Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: Germany 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 124: Germany Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Germany Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: Germany 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 127: Germany Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Germany Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: Germany 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 130: Germany Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Germany Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: Germany 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 133: Italy Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Italy Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 135: Italy 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 136: Italy Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Italy Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 138: Italy 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 139: Italy Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Italy Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 141: Italy 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 142: Italy Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Italy Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 144: Italy 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 145: UK Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 146: UK Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 147: UK 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 148: UK Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 149: UK Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 150: UK 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 151: UK Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 152: UK Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 153: UK 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 154: UK Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 155: UK Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 156: UK 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 157: Spain Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Spain Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 159: Spain 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 160: Spain Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Spain Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 162: Spain 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 163: Spain Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Spain Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 165: Spain 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 166: Spain Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Spain Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 168: Spain 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 169: Russia Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Russia Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 171: Russia 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 172: Russia Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Russia Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 174: Russia 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 175: Russia Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Russia Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 177: Russia 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 178: Russia Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Russia Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 180: Russia 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 181: Rest of Europe Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Rest of Europe Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 183: Rest of Europe 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 184: Rest of Europe Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Rest of Europe Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 186: Rest of Europe 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 187: Rest of Europe Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Rest of Europe Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 189: Rest of Europe 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 190: Rest of Europe Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Rest of Europe Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 192: Rest of Europe 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 193: Asia-Pacific Current & Future Analysis for Infectious Disease Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 194: Asia-Pacific Historic Review for Infectious Disease Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 195: Asia-Pacific 15-Year Perspective for Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 196: Asia-Pacific Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Asia-Pacific Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 198: Asia-Pacific 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 199: Asia-Pacific Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Asia-Pacific Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 201: Asia-Pacific 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 202: Asia-Pacific Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Asia-Pacific Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 204: Asia-Pacific 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 205: Asia-Pacific Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Asia-Pacific Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 207: Asia-Pacific 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 208: Australia Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Australia Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 210: Australia 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 211: Australia Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Australia Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 213: Australia 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 214: Australia Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 215: Australia Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 216: Australia 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 217: Australia Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 218: Australia Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 219: Australia 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 220: India Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 221: India Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 222: India 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 223: India Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 224: India Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 225: India 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 226: India Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 227: India Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 228: India 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 229: India Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 230: India Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 231: India 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 232: South Korea Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 233: South Korea Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 234: South Korea 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 235: South Korea Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 236: South Korea Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 237: South Korea 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 238: South Korea Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 239: South Korea Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 240: South Korea 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 241: South Korea Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 242: South Korea Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 243: South Korea 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 244: Rest of Asia-Pacific Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 245: Rest of Asia-Pacific Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 246: Rest of Asia-Pacific 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 247: Rest of Asia-Pacific Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 248: Rest of Asia-Pacific Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 249: Rest of Asia-Pacific 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 250: Rest of Asia-Pacific Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 251: Rest of Asia-Pacific Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 252: Rest of Asia-Pacific 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 253: Rest of Asia-Pacific Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 254: Rest of Asia-Pacific Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 255: Rest of Asia-Pacific 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 256: Latin America Current & Future Analysis for Infectious Disease Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 257: Latin America Historic Review for Infectious Disease Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 258: Latin America 15-Year Perspective for Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 259: Latin America Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 260: Latin America Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 261: Latin America 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 262: Latin America Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 263: Latin America Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 264: Latin America 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 265: Latin America Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 266: Latin America Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 267: Latin America 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 268: Latin America Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 269: Latin America Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 270: Latin America 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 271: Argentina Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 272: Argentina Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 273: Argentina 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 274: Argentina Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 275: Argentina Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 276: Argentina 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 277: Argentina Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 278: Argentina Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 279: Argentina 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 280: Argentina Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 281: Argentina Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 282: Argentina 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 283: Brazil Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 284: Brazil Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 285: Brazil 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 286: Brazil Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 287: Brazil Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 288: Brazil 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 289: Brazil Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 290: Brazil Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 291: Brazil 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 292: Brazil Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 293: Brazil Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 294: Brazil 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 295: Mexico Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 296: Mexico Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 297: Mexico 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 298: Mexico Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 299: Mexico Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 300: Mexico 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 301: Mexico Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 302: Mexico Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 303: Mexico 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 304: Mexico Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 305: Mexico Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 306: Mexico 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 307: Rest of Latin America Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 308: Rest of Latin America Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 309: Rest of Latin America 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 310: Rest of Latin America Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 311: Rest of Latin America Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 312: Rest of Latin America 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 313: Rest of Latin America Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 314: Rest of Latin America Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 315: Rest of Latin America 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 316: Rest of Latin America Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 317: Rest of Latin America Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 318: Rest of Latin America 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 319: Middle East Current & Future Analysis for Infectious Disease Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 320: Middle East Historic Review for Infectious Disease Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 321: Middle East 15-Year Perspective for Infectious Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 322: Middle East Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 323: Middle East Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 324: Middle East 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 325: Middle East Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 326: Middle East Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 327: Middle East 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 328: Middle East Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 329: Middle East Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 330: Middle East 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 331: Middle East Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 332: Middle East Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 333: Middle East 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 334: Iran Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 335: Iran Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 336: Iran 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 337: Iran Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 338: Iran Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 339: Iran 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 340: Iran Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 341: Iran Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 342: Iran 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 343: Iran Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 344: Iran Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 345: Iran 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 346: Israel Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 347: Israel Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 348: Israel 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 349: Israel Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 350: Israel Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 351: Israel 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 352: Israel Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 353: Israel Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 354: Israel 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 355: Israel Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 356: Israel Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 357: Israel 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 358: Saudi Arabia Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 359: Saudi Arabia Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 360: Saudi Arabia 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 361: Saudi Arabia Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 362: Saudi Arabia Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 363: Saudi Arabia 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 364: Saudi Arabia Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 365: Saudi Arabia Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 366: Saudi Arabia 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 367: Saudi Arabia Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 368: Saudi Arabia Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 369: Saudi Arabia 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 370: UAE Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 371: UAE Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 372: UAE 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 373: UAE Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 374: UAE Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 375: UAE 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 376: UAE Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 377: UAE Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 378: UAE 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 379: UAE Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 380: UAE Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 381: UAE 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 382: Rest of Middle East Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 383: Rest of Middle East Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 384: Rest of Middle East 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 385: Rest of Middle East Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 386: Rest of Middle East Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 387: Rest of Middle East 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 388: Rest of Middle East Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 389: Rest of Middle East Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 390: Rest of Middle East 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 391: Rest of Middle East Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 392: Rest of Middle East Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 393: Rest of Middle East 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 394: Africa Current & Future Analysis for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 395: Africa Historic Review for Infectious Disease Diagnostics by Product & Service - Assays, Kits, & Reagents, Instruments and Services and Software Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 396: Africa 15-Year Perspective for Infectious Disease Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assays, Kits, & Reagents, Instruments and Services and Software for the Years 2012, 2020 & 2027
    • TABLE 397: Africa Current & Future Analysis for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 398: Africa Historic Review for Infectious Disease Diagnostics by Disease Type - Hepatitis, HIV, HAI, HPV, TB and Influenza Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 399: Africa 15-Year Perspective for Infectious Disease Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis, HIV, HAI, HPV, TB and Influenza for the Years 2012, 2020 & 2027
    • TABLE 400: Africa Current & Future Analysis for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 401: Africa Historic Review for Infectious Disease Diagnostics by Technology - Immunodiagnostics, PCR and NGS Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 402: Africa 15-Year Perspective for Infectious Disease Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunodiagnostics, PCR and NGS for the Years 2012, 2020 & 2027
    • TABLE 403: Africa Current & Future Analysis for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 404: Africa Historic Review for Infectious Disease Diagnostics by End-Use - Hospital and Research Institute Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 405: Africa 15-Year Perspective for Infectious Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospital and Research Institute for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 41
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.